Investigational drug · Phase 2
Belvarafenib
Also called: HM95573
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced or Metastatic Melanoma, Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "Belvarafenib"
First trial start
2021
Jan 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Belvarafenib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic Melanoma
- Solid Tumors
Largest trials
Live from ClinicalTrials.gov: studies naming "Belvarafenib" as an intervention, largest first.
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04589845 · 920 participants (planned) · Start Jan 18, 2021 · Primary completion Sep 25, 2032
Drug: Entrectinib; Entrectinib and 9 more · For: Solid Tumors
Sites: Goodyear, Arizona; Los Angeles, California; Newport Beach, California · 112 sites in all
- HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid TumorsStatus unknown
Hanmi Pharmaceutical Company LimitedIndustry
NCT03284502 · 148 participants · Start May 22, 2017 · Primary completion Sep 30, 2024
Drug: HM95573, cobimetinib; HM95573, cetuximab and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Goyang-si, South Korea; Seongnam-si, South Korea; Hwasun, South Korea · 9 sites in all
- A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04835805 · 65 participants · Start May 13, 2021 · Primary completion Dec 31, 2026
Drug: Belvarafenib; Cobimetinib and 1 more · For: Melanoma
Sites: San Francisco, California; Aurora, Colorado; Iowa City, Iowa · 20 sites in all
Hanmi Pharmaceutical Company LimitedIndustry
NCT07449754 · 45 participants (planned) · Start Feb 12, 2026 · Primary completion Sep 2029
Drug: Belvarafenib · For: Advanced or Metastatic Melanoma
Sites: Seongnam-si, South Korea; Hwasun, South Korea; Busan, South Korea · 10 sites in all
Samsung Medical CenterAcademic, hospital or other
NCT07688356 · 30 participants (planned) · Start Jun 15, 2026 · Primary completion Jun 30, 2028
Drug: Belvarafenib · For: Primary Brain Tumor; Metastatic Brain Tumor
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathway.
Cai F, Huang F, Goncalves C, et al. · Cell Death Dis 2026
- Overloading And unpacKing (OAK) - droplet-based combinatorial indexing for ultra-high throughput single-cell multiomic profiling.
Wu B, Bennett HM, Ye X, et al. · Nat Commun 2024
- Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma.
Goetz A, Shanahan F, Brooks L, et al. · Cancers (Basel) 2024
- Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma.
Goetz A, Shanahan F, Brooks L, et al. · bioRxiv 2024
- Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.
Kim KH, Cho S, Jeong Y, et al. · Oncologist 2024
- Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase.
Rohrer L, Spohr C, Beha C, et al. · Cell Commun Signal 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.